我武生物：终止烟曲霉点刺液研发项目

Core Viewpoint - The company has decided to terminate the research and development project for the allergen skin prick solution for Aspergillus, which will not affect its other research pipelines and operational activities [1] Group 1: Project Termination - The management has announced the termination of the Aspergillus skin prick solution R&D project and will not proceed with further clinical trials [1] - The drug was intended for the auxiliary diagnosis of type I hypersensitivity diseases caused by Aspergillus sensitization, but phase I clinical trials showed delayed reactions that could not be resolved through pharmaceutical means [1] Group 2: Financial Impact - The termination of this project is expected to reduce the company's total profit by 4.7684 million yuan and net profit by 3.3379 million yuan in 2025 [1] Group 3: Current Product Portfolio - The company has already launched 8 types of allergen skin prick solutions, indicating a diversified product portfolio that remains unaffected by this project termination [1]